RBGPF Stock Recent News

Reckitt, a consumer goods producer, has experienced a decline in share price due to concerns over its nutrition business and ongoing legal issues. Despite underwhelming business performance, Reckitt's hygiene brands have shown growth and the company forecasts 2-4% net revenue growth for the current year. The company's share price has been overly punished, presenting an attractive valuation opportunity with a P/E ratio of 14 and strong brand assets.

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) reported a robust first quarter, signalling significant operational improvements under its new leadership, according to research by UBS. This comes after a year marked by challenges, notably in the US nutrition sector which had affected previous quarterly performances.

Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) has been upgraded to 'hold' from 'underperform' by Jefferies, bumping its valuation up by £3 a share to £44. In a note entitled Time To Use The Slack That's Been Given, the American investment bank points out the stock has fallen 23% year-to-date amid worries over the cost of baby formula litigation.

Reckitt Benckiser saw modest gains on Monday, following the share-price slide that erased some £5.6 billion ($7.1 billion) of market value.

Reckitt Beckinser Group said Friday it will seek to overturn a court ruling this week that awarded $60 million in damages to the family of a baby that died after being fed Enfamil infant formula, made by the British conglomerate's Mead Johnson Nutrition unit.

Reckitt Benckiser Group plc (RBGPF) Q4 2023 Earnings Call Transcript

Shares in the Nurofen maker Reckitt Benckiser Group PLC (LSE:RKT, ETR:3RB) fell 11% with the market spooked by its fourth-quarter sales miss and a £55 million revenue hit related to compliance issues at two of its Middle East operations. At 11.05 am, the stock was off 654p at 5,184p after the company revealed the trading drag was the result of lower-than-expected demand for cold and flu remedies and voluntary recall of its Nutramigen infant formula.

Any hopes that Taylor Wimpey might 'surprise on the upside' have seemingly been dashed by the CMA probe announced this week

Shares of Reckitt Benckiser have underperformed in recent years, and they now trade at a meaningful discount to global peers. Performance has been somewhat lumpy due to various one-time, non-company-specific factors, but growth is roughly landing where I thought it could at previous coverage. At around 17x EPS, Reckitt trades at a discount to both is historical average and global peers, and the stock looks priced for attractive medium-term returns.

The company said that most, if not all, of the possibly contaminated product has already been consumed.